LFG
AVBP icon

Larson Financial Group’s ArriVent BioPharma AVBP Stock Holding History

Larson Financial Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.62K Hold
277
– – ﹤0.01% 2434
2026
Q1 		$6.39K Sell
277
-191
-41% -$4.31K ﹤0.01% 2481
2025
Q4 		$9.42K Buy
468
+454
+3,243% +$9.45K ﹤0.01% 2147
2025
Q3 		$258 Buy
+14
New +$275 ﹤0.01% 3223

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Larson Financial Group's AVBP Position: Q2 2026 in Review

Larson Financial Group held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 277 shares worth $9.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2434.

Larson Financial Group first reported a position in AVBP in Q3 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Larson Financial Group held 277 shares of ArriVent BioPharma worth $9.62K as of Q2 2026.
  • Larson Financial Group left its ArriVent BioPharma share count unchanged in Q2 2026.
  • ArriVent BioPharma made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2434 holding.
  • Larson Financial Group first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.